Global Mice Model Market Size Industry Analysis, Pricing and Opportunities by Region with Competitive Landscape Forecast 2032

The Mice Model Market size was valued at USD 1.71 Billion in 2025 and the total Mice Model revenue is expected to grow at a CAGR of 6.8% from 2026 to 2032, reaching nearly USD 2.71 Billion.

Global Mice Model Market Overview:

This growth is fuelled by several factors. Advancements in creating new and improved mice models are making them more relevant for research. The rise of personalized medicine is increasing the demand for these models to test the effectiveness of treatments tailored to individual patients. The increasing pipelines of pharmaceutical and biopharmaceutical companies necessitate more preclinical testing, further driving the mice model market. The market also faces challenges. Ethical concerns surrounding animal testing and regulations aimed at ensuring the ethical use of animals hinder growth. Additionally, the development of alternative testing methods potentially replace the need for mice models in some instances. Despite these challenges, the mice model market is expected to maintain its upward trajectory due to the ongoing need for reliable preclinical testing in various research fields.

To know about the Research Methodology:-Request Free Sample Report

Advancements in gene editing techniques

The emergence of CRISPR gene editing is a game-changer for the mice model market. Earlier, generating mice with specific diseases or mutations was a laborious and error-prone process. This limited the accuracy and reliability of preclinical testing, a critical bottleneck in drug discovery. However, CRISPR offers a much faster, more targeted, and cost-effective approach to manipulating the mouse genome. This translates to mice models that more faithfully mimic human diseases. For instance, scientists now introduce disease-causing mutations with pinpoint accuracy, creating highly relevant models for studying disease progression and potential treatments. The impact goes beyond just mimicking diseases. CRISPR allows for the development of humanized mice by incorporating specific human genes or tissues. This significantly narrows the gap between preclinical testing in mice and human trials, accelerating the entire drug development process. The ease and precision of CRISPR editing streamline the creation of sophisticated and human-relevant mice models. This translates to faster and more reliable preclinical testing, ultimately fuelling the growth of the mice model market. This trend to continue, with increasing demand for these improved models driving Mice Model market growth during the forecast period.

The rise of personalized medicine is driving a significant force within the mice model market.

The increased need for tailored preclinical testing. Traditionally, drug development relied on a "one-size-fits-all approach, leading to treatments that weren't always effective for everyone. However, personalized medicine focuses on individual patient needs, requiring therapies targeted to specific genetic variations. This shift necessitates a more nuanced approach to preclinical testing. Here's where the mice model market comes in. Mice with precise genetic modifications, mirroring specific patient mutations, is used to evaluate the efficacy and safety of personalized treatments. This allows researchers to test how a drug work for a particular patient population before moving to human trials. The ability to create these highly customized models with CRISPR and other gene editing advancements is a boon for the mice model market. It fosters a more efficient drug development pipeline, with therapies demonstrably effective for specific patient groups reaching human trials faster. This not only benefits pharmaceutical companies but also accelerates the delivery of life-saving treatments to patients in need. As personalized medicine takes centre stage, the ability to create highly specific mice models remain a crucial tool in developing effective therapies for a wider range of patients.

Growing pipeline of pharmaceutical and biopharmaceutical companies.

The pharmaceutical and biopharmaceutical landscape is experiencing a surge in new drug discovery and development activity, with a continuously growing pipeline of potential treatments. This trend has a significant positive impact on the mice model market. These companies rely heavily on preclinical testing to evaluate the safety and efficacy of potential drugs before human trials commence. As their pipelines increase, the demand for robust and reliable preclinical testing solutions within the mice model market grows in tandem.

The mice model market offers a powerful tool for pharmaceutical companies the ability to create disease models in mice that closely mimic human conditions. This allows researchers to assess the potential effectiveness and potential side effects of new drugs in a controlled environment. With a growing number of drug candidates, the need for these in-vivo models within the mice model market becomes ever more crucial. Furthermore, the increasing focus on novel therapies, particularly those targeting specific diseases or patient populations, necessitates even more specialized testing models. The mice model market cater to this demand by providing mice with specific genetic modifications or disease states that mirror the target population. This tailored testing approach allows for a more accurate prediction of a drug's efficacy in humans, ultimately leading to a higher success rate in clinical trials.

The increasing pipeline of pharmaceutical and biopharmaceutical companies directly translates to a thriving mice model industry. As the need for preclinical testing solutions grows alongside the development of new drugs, the demand for sophisticated and specialized mice models within the mice model market continue to be a major driver of industry growth.

Global Mice Model Market Segment Analysis

The mice model market is segmented by oncology (cancer), neurology (brain and nervous system), metabolic diseases (like diabetes), immunology (immune system), cardiovascular diseases (heart and blood vessels), and other diseases. In 2024, the oncology segment holds the biggest share of the market. This dominance is driven by the significant increase in research funding dedicated to developing personalized cancer treatments. A prime example is the National Cancer Institute (NCI), which has allocated a substantial portion of its research budget, around USD xx billion, towards various cancer research areas, including brain and central nervous system cancers. This funding directly translates to a higher demand for specialized mice models specifically designed for cancer research.

Globally, breast and lung cancers were the most frequently diagnosed in 2020, accounting for 12.5% and 12.2% of all new cancer cases respectively. Colorectal cancer ranked third, with an estimated 1.9 million new cases diagnosed that year, representing 10.7% of global cases.

The increasing number of cancer patients creates a ripple effect. It highlights the need for effective treatments, which in turn fuels research using mice models. This drives demand for various types of mice models, ultimately leading to market growth.

Mice Model Market Segment Analysis:-

Based on model types mice model market is segmented into Inbred, Outbred, Hybrid, and genetically Engineered Mice. In 2024, inbred mice dominated the market. This dominance is due to their genetic uniformity. Because inbred mice are genetically identical, they offer consistent and reproducible results in research. This makes them ideal for studying complex traits and diseases, where researchers need to control for genetic variations. This advantage has significantly contributed to the growth of the inbred mice segment within the overall mice model market.

Mice Model Market Recent Developments:-

Global Mice Model Market Regional Analysis

North America is poised to be a leader in the mice model market during the forecast period. This growth is fuelled by a confluence of factors. Firstly, healthcare spending in the region is on the rise, which translates to more funding available for research and development. This increased investment directly translates to a greater demand for mice models to study various diseases and develop new treatments. The prevalence of both infectious and non-communicable diseases in North America is a growing concern. These diseases necessitate research using mice models to understand how they work and develop targeted therapies.

In addition, the market itself is quite active, with companies collaborating and forming agreements to push the boundaries of research using mice models. This collaborative spirit fosters innovation and fuels market growth within North America.

Mice Model Industry Ecosystem:-

Mice Model Market Scope: Inquire before buying

Mice Model Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (razil, Argentina Rest of South America)

Global Mice Model Market, Key Players:

Global Mice Model Providers in North America:
1. Laboratory Corporation of America Holdings (Burlington, North Carolina, USA)
2. Charles River Laboratories International, Inc. (Wilmington, Massachusetts, USA)
3. The Jackson Laboratory (Bar Harbor, Maine, USA)
4. Taconic Biosciences, Inc. (Germantown, New York, USA)
5. Crown Biosciences (San Diego, California, USA)
6. TransCure bioServices (Montreal, Quebec, Canada)
7. Cyagen Biosciences (Canton, Massachusetts, USA)
8. The Andersons, Inc. (Maumee, Ohio, USA)
9. Allentown, LLC (Allentown, New Jersey, USA))
Global Mice Model Providers in Europe:
10. Envigo (Huntingdon, Cambridgeshire, UK) [Previously known as Harlan Laboratories]
11. Janvier Labs (Yvonné, France)
12. Genoway (Lyon, France)
13. Ingenious Targeting Laboratory (Ghent, Belgium)
Global Mice Model Providers in Asia-Pacific:
14. Trans Genic, Inc. (Fukuoka, Japan)
15. Harbour Antibodies Bv (Harbin, China) [Harbour Biomed subsidiary]
16. PolyGene (Beijing, China)
17. GVK BIO (Hyderabad, India)
18. Ozgene Pty Ltd. (Brisbane, Queensland, Australia)

FAQs:
2. Which region has the largest share in Global Mice Model Market?
Ans: North America region holds the highest share in 2025.

1. What was the Global Mice Model Market size in 2025?
Ans: The Global Mice Model Market size was USD 1.71 Billion in 2025.

3. What segments are covered in Global Mice Model market?
Ans: Global Mice Model Market is segmented into Model Type, Technology, Application, End-User and region.

4. Who are the key players in Global Mice Model market?
Ans: The important key players in the Global Mice Model Market are – Laboratory Corporation of America Holdings (Burlington, North Carolina, USA), Charles River Laboratories International, Inc. (Wilmington, Massachusetts, USA), The Jackson Laboratory (Bar Harbor, Maine, USA), Taconic Biosciences, Inc. (Germantown, New York, USA), Crown Biosciences (San Diego, California, USA), TransCure bioServices (Montreal, Quebec, Canada), Cyagen Biosciences (Canton, Massachusetts, USA), The Andersons, Inc. (Maumee, Ohio, USA),Allentown, LLC (Allentown, New Jersey, USA)and Others.